{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:25Z","timestamp":1791327445191,"version":"4.3.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Anti-Calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) have shown significant efficacy in preventing migraine. However, there have been limited reports of adverse events (AEs) after marketing, particularly for eptinezumab launched in 2020. The study aimed to mine and analyze the AE signals with four anti-CGRP mAbs from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to gain insights into the safety profile of these medications post-marketing.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> All AE reports on the four anti-CGRP mAbs (erenumab, galcanezumab, fremanezumab, and eptinezumab) were retrieved from the FAERS database from the first quarter (Q1) of 2018 to Q1 of 2023. Disproportionality analysis was measured by reporting odd ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) to identify potential AE signals. Comparisons were made between the four drugs in terms of AEs.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 38,515 reports of erenumab, 19,485 reports of galcanezumab, 5,332 reports of fremanezumab, and 2,460 reports of eptinezumab were obtained, mostly reported in the second to third year after launch in the market. The common AEs to erenumab included constipation (17.93%), injection site pain (14.08%), and alopecia (7.23%). The AEs that occurred more frequently with galcanezumab included injection site pain (24.37%), injection site erythema (5.35%), and injection site haemorrhage (4.97%). Common AEs related to fremanezumab were injection site pain (13.10%), injection site erythema (7.02%), and injection site pruritus (5.47%). Fatigue (13.54%), throat irritation (9.02%), and pruritus (8.20%) were the most common AEs with eptinezumab. In addition, there are new AEs that were not listed in the drug instructions but occurred concurrently with multiple drugs, such as Raynaud\u2019s phenomenon, weight increase, menstrual disorders, throat tightness, and paraesthesia oral.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Common AE signals of the four anti-CGRP mAbs and new AE signals were found to provide a reference for clinical drug selection in clinical practice.<\/jats:p>","DOI":"10.3389\/fphar.2023.1257282","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T04:12:24Z","timestamp":1704773544000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system"],"prefix":"10.3389","volume":"14","author":[{"given":"Wenfang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1111\/head.13956","article-title":"Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study","volume":"60","author":"Alex","year":"2020","journal-title":"Headache"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/TCRM.S137144","article-title":"Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs","volume":"13","author":"Arora","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"B3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11916-020-00880-w","article-title":"Cephalgia alopecia","volume":"24","author":"Bedrin","year":"2020","journal-title":"Curr. Pain Headache Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1046\/j.1468-2982.2003.00468.x","article-title":"Epidemiology of headache in an English district","volume":"23","author":"Boardman","year":"2003","journal-title":"Cephalalgia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e217934","DOI":"10.1001\/jamanetworkopen.2021.7934","article-title":"Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon","volume":"4","author":"Breen","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1055\/s-0037-1607393","article-title":"Migraine in women","volume":"37","author":"Broner","year":"2017","journal-title":"Semin. Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/head.13291","article-title":"Understanding menstrual migraine","volume":"58","author":"Calhoun","year":"2018","journal-title":"Headache"},{"key":"B8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1056\/NEJMcp1605502","article-title":"Migraine","volume":"377","author":"Charles","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"G36","DOI":"10.1152\/ajpgi.00464.2006","article-title":"Role of calcitonin receptor-like receptor in colonic motility and inflammation","volume":"293","author":"Clifton","year":"2007","journal-title":"Am. J. Physiol.-Gastroint. Liver Physiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/14740338.2021.1933941","article-title":"Safety and tolerability evaluation of erenumab for the preventive treatment of migraine","volume":"20","author":"Deligianni","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s42466-020-00057-1","article-title":"Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: addition to the S1 guideline: therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society","volume":"2","author":"Diener","year":"2020","journal-title":"Neurol. Res. Pract."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/head.13596","article-title":"Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists","volume":"59","author":"Evans","year":"2019","journal-title":"Headache"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-022-01424-w","article-title":"Calcitonin gene-related peptide-targeting drugs and Raynaud\u2019s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database","volume":"23","author":"Gerard","year":"2022","journal-title":"J. Headache Pain"},{"key":"B16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.410230214","article-title":"Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system","volume":"23","author":"Goadsby","year":"1988","journal-title":"Ann. Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1136\/bmj.e289","article-title":"Diagnosis and management of Raynaud\u2019s phenomenon","volume":"344","author":"Goundry","year":"2012","journal-title":"BMJ-British Med. J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3109\/00016489309135836","article-title":"Regulatory peptides in the human larynx and recurrent nerves","volume":"113","author":"Hauser-Kronberger","year":"1993","journal-title":"Acta Oto-Laryngol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The weber effect and the United States Food and drug administration\u2019s adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"820006","DOI":"10.3389\/fphys.2021.820006","article-title":"Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide\u2019s motor-stimulating and prosecretory function in the intestine","volume":"12","author":"Holzer","year":"2021","journal-title":"Front. Physiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/2168479013514236","article-title":"A review of statistical methods for safety surveillance","volume":"48","author":"Huang","year":"2014","journal-title":"Ther. Innov. Regul. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1177\/03331024221111526","article-title":"Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine","volume":"42","author":"Iannone","year":"2022","journal-title":"Cephalalgia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","article-title":"Real-world effectiveness and tolerability of erenumab: a retrospective cohort study","volume":"40","author":"Kanaan","year":"2020","journal-title":"Cephalalgia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/head.14120","article-title":"Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: a novel patient-centered outcome","volume":"61","author":"Lipton","year":"2021","journal-title":"Headache"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-022-01435-7","article-title":"CGRP and PACAP-38 play an important role in diagnosing pediatric migraine","volume":"23","author":"Liu","year":"2022","journal-title":"J. Headache Pain"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e04625","DOI":"10.1002\/ccr3.4625","article-title":"Raynaud\u2019s phenomenon secondary to erenumab in a patient with chronic migraine","volume":"9","author":"Manickam","year":"2021","journal-title":"Clin. Case Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1467-789X.2009.00669.x","article-title":"Regulation of lipid metabolism by energy availability: a role for the central nervous system","volume":"11","author":"Nogueiras","year":"2010","journal-title":"Obes. Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","article-title":"Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy","volume":"21","author":"Ornello","year":"2020","journal-title":"J. Headache Pain"},{"key":"B31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/cells12010143","article-title":"Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data","volume":"12","author":"Pavelic","year":"2022","journal-title":"Cells"},{"key":"B32","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/jnr.23903","article-title":"Sex-related influences in migraine","volume":"95","author":"Pavlovic","year":"2017","journal-title":"J. Neurosci. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.npep.2012.07.008","article-title":"Effects of calcitonin gene-related peptide on the immune privilege of human hair follicles","volume":"47","author":"Pi","year":"2013","journal-title":"Neuropeptides"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/acn3.51360","article-title":"Plasma calcitonin gene-related peptide (CGRP) in migraine and endometriosis during the menstrual cycle","volume":"8","author":"Raffaelli","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/00001756-199703240-00015","article-title":"Possible involvement of neuropeptidergic sensory nerves in alopecia areata","volume":"8","author":"Rossi","year":"1997","journal-title":"Neuroreport"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3331024221143538","DOI":"10.1177\/03331024221143538","article-title":"Alopecia as an emerging adverse event to CGRP monoclonal antibodies: cases Series, evaluation of FAERS, and literature review","volume":"43","author":"Ruiz","year":"2023","journal-title":"Cephalalgia"},{"key":"B37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-021-00469-8","article-title":"New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and drug administration adverse event reporting system database","volume":"35","author":"Sessa","year":"2021","journal-title":"Biodrugs"},{"key":"B38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s12325-022-02346-4","article-title":"Adverse events reported with therapies targeting the CGRP pathway during the first 6 Months post-launch: a retrospective analysis using the FDA adverse events reporting system","volume":"40","author":"Silberstein","year":"2023","journal-title":"Adv. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"101109","DOI":"10.1016\/j.molmet.2020.101109","article-title":"Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases","volume":"46","author":"Sonne","year":"2021","journal-title":"Mol. Metab."},{"key":"B41","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","article-title":"Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"Sun","year":"2016","journal-title":"Lancet Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/head.14138","article-title":"Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study","volume":"61","author":"Takeshima","year":"2021","journal-title":"Headache"},{"key":"B43","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/path.1711640310","article-title":"Image analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud\u2019s phenomenon and systemic sclerosis","volume":"164","author":"Terenghi","year":"1991","journal-title":"J. Pathol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e12817","DOI":"10.1111\/dth.12817","article-title":"Injection site reactions with the use of biological agents","volume":"32","author":"Thomaidou","year":"2019","journal-title":"Dermatol. Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00455-021-10248-w","article-title":"Oropharyngeal dysphagia in older people is associated with reduced pharyngeal sensitivity and low substance P and CGRP concentration in saliva","volume":"37","author":"Tomsen","year":"2022","journal-title":"Dysphagia"},{"key":"B47","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00403-021-02247-6","article-title":"The association between alopecia areata and anxiety, depression, schizophrenia, and bipolar disorder: a population-based study","volume":"314","author":"Tzur","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/jcpt.13620","article-title":"Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: a retrospective cohort study","volume":"47","author":"Viudez-Martinez","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/phar.2725","article-title":"Alopecia signals associated with calcitonin gene-related peptide inhibitors in the treatment or prophylaxis of migraine: a pharmacovigilance study","volume":"42","author":"Woods","year":"2022","journal-title":"Pharmacotherapy"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1038\/s41598-019-39170-w","article-title":"Neuropeptides substance P and calcitonin gene related peptide accelerate the development and fibrogenesis of endometriosis","volume":"9","author":"Yan","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1257282\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T04:12:27Z","timestamp":1704773547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1257282\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":50,"alternative-id":["10.3389\/fphar.2023.1257282"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1257282","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"article-number":"1257282"}}